BioSpace News Archive

GenScript USA Inc., the world’s leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.

UCB today announced three collaborations aimed at examining the impact of seizure clusters on patient and caregiver quality of life.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

Medicover and FYR Diagnostics are proud to announce a new partnership focused on diagnostic test development and Precision Medicine.

Harmony Biosciences Holdings, Inc. today announced that Harmony’s management will participate in the following upcoming investor conference.

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.

PerkinElmer, Inc. today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity.

Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).

Sonoma Biotherapeutics, Inc. today announced the appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH, to its Board of Directors.